Anixa Biosciences, Inc. — FY2019 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended October 31, 2019, with FY2018 as the comparable period; it is an annual report, not a standalone fourth-quarter report. Anixa is an early-stage biotechnology company developing the Cchek cancer-diagnostics platform, an ovarian-cancer cell therapy and a breast-cancer vaccine. Its reported revenue came from legacy patent licensing, not its cancer programs.
Key financial metrics
| Metric | FY2019 | FY2018 |
|---|---|---|
| Revenue | $250,000 | $1,112,500 |
| Research and development expense | $5.473 million | $6.813 million |
| General and administrative expense | $5.663 million | $6.912 million |
| Operating loss | $11.890 million | $14.289 million |
| Net loss | $11.819 million | $14.243 million |
| Net loss attributable to common stockholders | $11.647 million | $13.996 million |
| Basic and diluted loss per share | $0.59 | $0.79 |
| Net cash used in operating activities | $4.741 million | $4.273 million |
Liquidity and balance sheet. At October 31, 2019, cash and cash equivalents were $3.492 million and short-term certificates of deposit were $2.350 million, totaling $5.842 million. Current assets were $6.093 million, current liabilities $1.481 million and working capital $4.612 million. Total assets were $6.294 million and total equity $4.812 million. The filing does not report borrowings or debt on the balance sheet. Management said on January 9, 2020 that available funds and expected cash flows were expected to support activities for the next 12 months, while warning that projections could differ from actual needs. No operating margin is presented; the company reported operating and net losses.
FY2019 financing cash inflow was $5.703 million, principally from $5.527 million raised through an at-the-market equity offering. Cash and cash equivalents increased by $436,000 year over year. The cash-flow statement reports operating cash use of $4.741 million; the MD&A elsewhere cites approximately $4.773 million, a difference the filing text does not reconcile.
Material changes versus FY2018
- Revenue fell by about 78%, reflecting fewer one-time patent-license payments; FY2019 revenue was from one license agreement versus two in FY2018. The company said legacy licensing was not expected to be a significant ongoing revenue source.
- Net loss narrowed to $11.819 million from $14.243 million. R&D and G&A expenses declined, primarily due to lower share-based compensation; total operating expenses also included a $419,000 patent-asset impairment.
- Operating cash use increased to $4.741 million from $4.273 million. Financing proceeds increased, mainly because of higher ATM share issuance.
- Patent assets were written down during FY2019 and had a reported carrying value of zero at year-end. The company also recorded higher patent amortization than in FY2018.
Outlook, commentary and risks
- Cchek PCC: Anixa announced the commercial launch of its prostate-cancer confirmation test in December 2019, after year-end, following independent laboratory validation. ResearchDx’s validation reported 96% sensitivity and 45% specificity. The company expected broad U.S. availability by April 2020 and was working on marketing, physician education and reimbursement. These are company expectations, not guarantees; the test was a laboratory-developed test run by its CLIA-certified partner.
- Therapeutics: Anixa expected to file an ovarian-cancer cell-therapy IND by the end of 2020 and suggested a clinical trial could begin as early as the second quarter of 2021, subject to FDA review. It expected to file an IND for the breast-cancer vaccine in 2020. Both programs remained preclinical; no human trials had begun.
- Funding and dilution: The company stated it may need additional capital and had an effective ATM facility allowing up to $50 million of common-stock sales, with sales beginning in November 2019. Further equity or convertible-debt financing could dilute shareholders; funding may not be available on acceptable terms.
- Development and commercialization risks: Key uncertainties include whether early diagnostic results will replicate in broader studies, clinical utility and reimbursement for Cchek, regulatory requirements, trial and manufacturing readiness, patient enrollment, product safety, competition and reliance on collaborators and licensed intellectual property. The company disclosed substantially greater resources at many competitors and no product revenue from its cancer programs to date.
- Unusual items and contingencies: A shareholder derivative-action settlement required repricing certain previously repriced options and changes to governance; claims were dismissed, and defendants denied wrongdoing. A disputed trade payable of approximately $337,000 was discharged after the vendor’s collection right expired. The company reported no material pending legal proceedings beyond ordinary-course matters and patent enforcement actions.
Most important facts for investors to verify
- Whether Cchek PCC achieved physician adoption, broad availability and reimbursement, and how real-world test performance compares with the reported validation results.
- Updated cash burn, remaining liquidity, ATM share sales and potential dilution, particularly given the company’s stated 12-month funding estimate and continuing development costs.
- Progress, timing and FDA feedback on the CAR-T and breast-vaccine IND plans, including clinical-grade manufacturing and any trial authorization.
- The basis for the reported operating cash-use discrepancy: $4.741 million in the cash-flow statement versus approximately $4.773 million in MD&A.
- Share-based compensation and outstanding equity awards, as well as obligations under the Wistar and Cleveland Clinic licenses and research collaborations.